SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-23-036113
Filing Date
2023-05-04
Accepted
2023-05-04 08:10:35
Documents
61
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0323_protaratherap.htm   iXBRL 10-Q 852646
2 CERTIFICATION f10q0323ex31-1_protaratherap.htm EX-31.1 12561
3 CERTIFICATION f10q0323ex31-2_protaratherap.htm EX-31.2 12496
4 CERTIFICATION f10q0323ex32-1_protaratherap.htm EX-32.1 7122
  Complete submission text file 0001213900-23-036113.txt   4158385

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE tara-20230331.xsd EX-101.SCH 49490
6 XBRL CALCULATION FILE tara-20230331_cal.xml EX-101.CAL 21984
7 XBRL DEFINITION FILE tara-20230331_def.xml EX-101.DEF 185628
8 XBRL LABEL FILE tara-20230331_lab.xml EX-101.LAB 385903
9 XBRL PRESENTATION FILE tara-20230331_pre.xml EX-101.PRE 198733
55 EXTRACTED XBRL INSTANCE DOCUMENT f10q0323_protaratherap_htm.xml XML 454936
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

IRS No.: 204580525 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36694 | Film No.: 23886647
SIC: 2836 Biological Products, (No Diagnostic Substances)